Loading institutional data...
Loading institutional data...
Held by 239 of 2,417 reporting institutions (96th percentile) — extremely crowded.
Data as of Q3 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading insider activity...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Ranked against 37 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IQV | $45.3B | 35.1× | 17.8× | 2.8× | 5.9% | — | 8.3% | 20.9% | 6.1% | 4.1× | 319 |
| PAYX | $38.9B | 22.4× | 14.4× | 6.0× | 16.9% | 74.3% | 27.0% | 47.1% | 21.2% | 1.2× | 517 |
| INCY | $23.7B | 18.2× | 12.8× | 4.6× | 21.2% | 92.8% | 25.0% | 24.9% | 24.9% | -1.9× | 239 |
| MEDP | $19.0B | 44.3× | 32.8× | 7.5× | 20.0% | — | 17.8% | 98.3% | 98.3% | -0.9× | 174 |
| CRL | $18.0B | — | 41.4× | 4.5× | -0.9% | — | -3.6% | -4.6% | -4.6% | -0.5× | 132 |
| ICLR | $16.1B | 74.3× | 22.2× | 2.0× | 0.8% | — | 2.8% | 2.5% | 1.9% | 2.7× | 86 |
| ULS | $15.2B | 47.2× | 21.7× | 5.0× | 6.4% | 49.5% | 10.6% | 25.8% | 18.5% | 0.3× | 72 |
| IT | $14.2B | 23.3× | 12.6× | 2.2× | 3.7% | 68.8% | 11.2% | 228% | 22.1% | 1.0× | 163 |
| BAH | $10.0B | 12.2× | 11.1× | 0.9× | -6.4% | 52.7% | 7.6% | 77.0% | 16.9% | 2.7× | 118 |
| TTEK | $9.8B | 41.0× | 22.2× | 1.8× | 4.7% | 17.7% | 4.6% | 13.9% | 9.7% | 1.3× | 123 |
| ACM | $8.2B | 15.1× | 6.2× | 0.5× | 0.2% | 7.5% | 3.5% | 22.5% | 22.5% | -1.5× | 125 |
| G | $6.5B | 12.4× | 8.8× | 1.3× | 6.6% | 36.0% | 10.9% | 21.7% | 13.5% | 0.8× | 112 |
| FCN | $5.0B | 22.0× | 11.7× | 1.3× | 2.4% | 32.1% | 7.1% | 15.6% | 12.9% | 0.2× | 66 |
| VSEC | $4.4B | 281.9× | 35.3× | 3.9× | 41.5% | — | 1.1% | 0.8% | 0.7% | 1.7× | 74 |
| EXPO | $3.7B | 37.8× | — | 6.4× | 4.2% | — | 18.2% | 27.2% | 27.2% | — | 76 |
| HURN | $3.1B | 33.0× | 16.9× | 1.8× | 11.7% | — | 6.2% | 19.9% | 10.1% | 2.3× | 48 |
| VVX | $2.5B | 32.9× | 17.1× | 0.6× | 3.7% | 8.3% | 1.7% | 7.2% | 3.6% | 5.2× | 62 |
| NEO | $2.3B | — | — | 3.2× | 10.1% | 43.2% | -14.9% | -12.9% | -9.2% | — | 56 |
| ASTH | $1.8B | 79.6× | 19.5× | 0.6× | 56.4% | — | 0.7% | 2.9% | 1.2% | 4.9× | 35 |
| ICFI | $1.7B | 19.4× | 10.4× | 0.9× | -7.3% | 37.2% | 4.9% | 8.9% | 6.4% | 1.9× | 35 |
| WLDN | $1.2B | 22.1× | 18.4× | 1.7× | 20.5% | 37.5% | 7.7% | 17.2% | 14.9% | -0.3× | 37 |
| BWMN | $711M | 58.7× | 20.6× | 1.4× | 14.9% | 53.4% | 2.6% | 4.9% | 4.0% | 1.3× | 22 |
| MG | $644M | 38.1× | 11.1× | 0.9× | -0.8% | 28.2% | 2.3% | 7.2% | 4.1% | 2.1× | 24 |
| ONT | $523M | — | 33.3× | 0.6× | 19.3% | 40.3% | -0.1% | -0.2% | -0.1% | 11.5× | — |
| NRC | $498M | 0.5× | — | 3.6× | -4.0% | — | 8.4% | 82.9% | 12.5% | — | 22 |
Peers = companies sharing INCY's sector (Services-Commercial Physical & Biological Research) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on $1.39B FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 25%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $3.10B (at 2025-12-31) covers all $840.9M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2014-12-31 (10-K). The cash figure is from 2025-12-31, so the two are not the same balance-sheet date — the schedule has not been refiled since.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
Average free cash flow across the last 3 positive fiscal years (FY2023, FY2024, FY2025). Smooths the cycle. Stock compensation is NOT charged — it is added back inside operating cash flow.
To be worth $120.39 today, the market must believe free cash flow compounds 7.0%/yr for a decade (off $730.5M on the 3-yr avg basis).
On the basis ($486.7M) the requirement is 12.2%/yr. Shares issued to employees are added back in operating cash flow, so this basis treats them as free.
The market's 7.0% is more conservative than its 9-yr track record.
Default is 7.5% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.20B shares (market data) · net debt -$3.10B
mean 12.9% · volatility σ 183% · implied rate exceeded in 3/7 yrs
Central path = implied 7.0%/yr growth; shaded band = ±1σ (183%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.14B 100.0% | $4.24B 100.0% | $3.70B 100.0% | $3.39B 100.0% | $2.99B 100.0% | $2.67B 100.0% | $2.16B 100.0% | $1.88B 100.0% | $1.54B 100.0% | $1.11B 100.0% |
| Cost of Revenue | $372.1M 7.2% | $312.1M 7.4% | $255.0M 6.9% | $207.0M 6.1% | $151.0M 5.1% | $131.3M 4.9% | $114.2M 5.3% | $94.1M 5.0% | $79.5M 5.2% | $58.2M 5.3% |
| Cost of Products | — | — | — | — | — | — | — | — | $79.5M 5.2% | $58.2M 5.3% |
| Research & Development | $2.05B 39.9% | $2.61B 61.5% | $1.63B 44.0% | $1.59B 46.7% | $1.46B 48.8% | $2.22B 83.1% | $1.15B 53.5% | $1.20B 63.7% | $1.33B 86.3% | $581.9M 52.6% |
| Selling, General & Admin | $1.38B 26.8% | $1.24B 29.3% | $1.16B 31.3% | $1.00B 29.5% | $739.6M 24.8% | $516.9M 19.4% | $468.7M 21.7% | $434.4M 23.1% | $366.3M 23.8% | $303.3M 27.4% |
| Total Operating Expenses | $3.63B 70.5% | $4.18B 98.6% | $3.08B 83.2% | $2.82B 82.9% | $2.40B 80.4% | $2.93B 109.9% | $1.76B 81.4% | $1.75B 93.1% | $1.78B 115.8% | $960.7M 86.9% |
| Operating Income | $1.51B 29.5% | $61.4M 1.4% | $620.5M 16.8% | $579.4M 17.1% | $585.8M 19.6% | -$263.7M -9.9% | $402.0M 18.6% | $129.2M 6.9% | -$243.4M -15.8% | $145.0M 13.1% |
| Interest Expense | $2.4M 0.0% | $2.3M 0.1% | $2.6M 0.1% | $2.7M 0.1% | $1.9M 0.1% | $2.2M 0.1% | $1.9M 0.1% | $1.5M 0.1% | $6.9M 0.4% | $38.7M 3.5% |
| Interest & Investment Income | $105.6M 2.1% | $128.7M 3.0% | $158.4M 4.3% | $40.5M 1.2% | — | — | — | — | — | — |
| Other Income (Expense), net | $25.1M 0.5% | $12.8M 0.3% | $13.9M 0.4% | -$519K -0.0% | $10.6M 0.4% | $23.2M 0.9% | $52.2M 2.4% | $31.8M 1.7% | $17.2M 1.1% | — |
| Pretax Income | $1.66B 32.4% | $316.6M 7.5% | $834.2M 22.6% | $529.1M 15.6% | $570.4M 19.1% | -$232.2M -8.7% | $486.8M 22.5% | $115.3M 6.1% | -$312.3M -20.3% | $107.4M 9.7% |
| Income Tax Expense | $377.8M 7.3% | $284.0M 6.7% | $236.6M 6.4% | $188.5M 5.6% | -$378.1M -12.7% | $63.5M 2.4% | $39.9M 1.8% | $5.9M 0.3% | $852K 0.1% | $3.2M 0.3% |
| Net Income | $1.29B 25.0% | $32.6M 0.8% | $597.6M 16.2% | $340.7M 10.0% | $948.6M 31.8% | -$295.7M -11.1% | $446.9M 20.7% | $109.5M 5.8% | -$313.1M -20.4% | $104.2M 9.4% |
| Per Share | ||||||||||
| EPS (Basic) | $6.59 | $0.16 | $2.67 | $1.53 | $4.30 | -$1.36 | $2.08 | $0.52 | -$1.53 | $0.55 |
| EPS (Diluted) | $6.41 | $0.15 | $2.65 | $1.52 | $4.27 | -$1.36 | $2.05 | $0.51 | -$1.53 | $0.54 |
| Weighted Avg Shares (Basic) | 195.2M | 207.1M | 223.6M | 222.0M | 220.4M | 218.1M | 214.9M | 212.4M | 204.6M | 187.9M |
| Weighted Avg Shares (Diluted) | 200.7M | 210.5M | 225.9M | 224.0M | 222.1M | 218.1M | 217.7M | 215.6M | 204.6M | 194.1M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-10-30
Where each multiple sits in its own 14-yr range · 25th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
ROE 25% against ROIC 25% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is 29.9% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 111.6× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 5.0 | 5.3 | 4.9 | 5.1 | 6.1 | 6.9 | 7.4 | 7.2 |
| R&D | 63.7 | 53.5 | 83.1 | 48.8 | 46.7 | 44.0 | 61.5 | 39.9 |
| SG&A | 23.1 | 21.7 | 19.4 | 24.8 | 29.5 | 31.3 | 29.3 | 26.8 |
| Operating Income | 6.9 | 18.6 | -9.9 | 19.6 | 17.1 | 16.8 | 1.4 | 29.5 |
| Income Tax | 0.3 | 1.8 | 2.4 | -12.7 | 5.6 | 6.4 | 6.7 | 7.3 |
| Net Income | 5.8 | 20.7 | -11.1 | 31.8 | 10.0 | 16.2 | 0.8 | 25.0 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on INCY: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Earns 40.2pts above its cost of capital, positive in 4 of the last 5 years.
| Period | ROIC | Cost of capital | Spread |
|---|---|---|---|
| FY2019 | 32.6% | 7.5% (today's — no rate published for this year) | 25.1pts |
| FY2020 | -15.2% | 7.5% (today's — no rate published for this year) | -22.8pts |
| FY2021 | 22.4% | 4.9% | 17.5pts |
| FY2022 | 26.3% | 6.9% | 19.4pts |
| FY2023 | 20.7% | 7.5% | 13.2pts |
| FY2024 | 2.3% | 9.3% | -7.0pts |
| FY2025 | 47.6% | 7.1% | 40.5pts |
| Now | 24.9% | 7.5% | 17.4pts |
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2016 | 94.7% | 13.1% | 9.4% |
| FY2017 | 94.8% | -15.8% | -20.4% |
| FY2018 | 95.0% | 6.9% | 5.8% |
| FY2019 | 94.7% | 18.6% | 20.7% |
| FY2020 | 95.1% | -9.9% | -11.1% |
| FY2021 | 94.9% | 19.6% | 31.8% |
| FY2022 | 93.9% | 17.1% | 10.0% |
| FY2023 | 93.1% | 16.8% | 16.2% |
| FY2024 | 92.6% | 1.4% | 0.8% |
| FY2025 | 92.8% | 29.5% | 25.0% |
Return on equity (25%) and return on invested capital (25%) are within a couple of points in FY2025, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
$133M of goodwill — 6% of invested capital. The gap is what was paid above the fair value of what was bought; it is real capital shareholders provided, so neither bar is the whole answer.
The spread was positive in only 4 of the last 5 years.
Converts 2.99x of reported profit into cash — adequate, without much margin.
Reported free cash flow is $1.39B; after share-based compensation it is $1.14B. The difference is a real cost that the cash flow statement adds back.
Covers interest 436.7x even after a 30% EBITDA decline.
| EBITDA decline | Interest coverage |
|---|---|
| 0% | 623.91x |
| 5% | 592.72x |
| 10% | 561.52x |
| 15% | 530.33x |
| 20% | 499.13x |
| 25% | 467.93x |
| 30% | 436.74x |
| 35% | 405.54x |
| 40% | 374.35x |
| 45% | 343.15x |
| 50% | 311.96x |
| 55% | 280.76x |
| 60% | 249.56x |
This schedule comes from a filing dated 2014-12-31, 4321 days old. Maturities are shown relative to that date, not to today.
Ladder as of 2014-12-31 (10-K); cash from the 2025-12-31 balance sheet; FCF from FY2025.
Balance sheet at 2025-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
Operating leases are $54,920,000 of the $54,920,000 total — a fixed obligation that does not appear in a headline debt figure.
At $116.80, free cash flow must compound 6.64%/yr for 10 years. It has done 14.0%/yr over 6 years.
| Fiscal year | FCF growth | Price requires |
|---|---|---|
| FY2020 | −149.3% | 6.6% |
| FY2022 | 56.9% | 6.6% |
| FY2023 | −46.0% | 6.6% |
| FY2024 | −33.2% | 6.6% |
| FY2025 | 332.0% | 6.6% |
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM.
The implied rate has been matched or beaten in 2 of the last 5 years.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
| Step | Amount | Running total |
|---|---|---|
| Net income | $1.29B | $1.29B |
| Share-based comp | $249M | $1.54B |
| Other non-cash & working capital | −$122M | $1.41B |
| Operating cash flow | $1.41B | $1.41B |
| Capex | −$25M | $1.39B |
| Free cash flow | $1.39B | $1.39B |
| FCF after SBC | $1.14B | $1.14B |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2020 | 23.5% | 56.1% | 32.5 points |
| FY2021 | 12.0% | 27.9% | 15.9 points |
| FY2022 | 13.7% | 4.6% | -9.0 points |
| FY2023 | 8.9% | 15.3% | 6.4 points |
| FY2024 | 14.8% | 14.7% | -0.0 points |
| FY2025 | 21.2% | 20.1% | -1.1 points |
| Fiscal year | DSO | DIO | DPO | Cash conversion cycle |
|---|---|---|---|---|
| FY2019 | 52.2 days | 36.4 days | 267.2 days | -178.6 days |
| FY2020 | 66 days | 45.7 days | 274.5 days | -162.9 days |
| FY2021 | 75.3 days | 67.5 days | 416.1 days | -273.3 days |
| FY2022 | 69.3 days | 74.1 days | 489.4 days | -346 days |
| FY2023 | 73.4 days | 90.1 days | 156.9 days | 6.7 days |
| FY2024 | 73.4 days | 68.9 days | 231 days | -88.7 days |
| FY2025 | 72.7 days | 99.1 days | 205.9 days | -34.1 days |
| Fiscal year | Accruals / assets |
|---|---|
| FY2019 | -7.7 percent |
| FY2020 | -4.8 percent |
| FY2021 | 4.0 percent |
| FY2022 | -10.8 percent |
| FY2023 | 1.5 percent |
| FY2024 | -5.6 percent |
| FY2025 | -1.8 percent |
Below the line, the asset base is being consumed faster than it is replaced.
Below the line for 3 consecutive years to the latest.
Depreciation here includes amortisation of acquired intangibles — goodwill written down over time, customer lists, acquired technology. Capex does not replace those and is not meant to, so an acquisitive or asset-light company sits below 1.0 permanently and correctly. The signal is cleanest for capital-intensive businesses, where the two measure the same physical base. For that reason this informs the earnings-quality verdict but never caps it.
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2025) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.
Last reported position per insider, carried forward. Steps can be a holding disclosed for the first time rather than a trade.
| Date | Insider | What it was | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-15 | 9 co-filers President, Global Head of R&D | Option exercise | 839 | $71.93 | $60k |
| 2026-10-15 | 9 co-filers President, Global Head of R&D | Option exercise | 423 | $61.76 | $26k |
| 2026-10-15 | 9 co-filers President, Global Head of R&D | Option exercise | 455 | $61.18 | $28k |
| 2026-10-15 | 9 co-filers President, Global Head of R&D |
Every row is classified by what it MEANT, not by its SEC code. A code is not a meaning: code P (“purchase”) also covers dividend reinvestment and employee stock purchase plans, and code S (“sale”) also covers 10b5-1 plan sales scheduled months earlier and option exercises sold the same day.
Across 30 days of all filings, $5.08bn of insider selling contained $3.50bn of plan sales and $0.46bn of exercise-and-sell. Only 29% was discretionary. Reading an unclassified feed badly overstates how much insiders decided.
Buys and sales are counted separately and never netted. They are different decisions by different people; a company where one officer bought while another sold is not “neutral”.
The holding line carries each insider's last reported position forward, so it shows the total held rather than a sawtooth of whoever traded that day. It covers only insiders who filed in the window.
“Filed late” counts calendar days past the two-business-day deadline with five days' grace, so a Thursday or Friday trade crossing a weekend is never flagged. It describes the company's filing discipline, not the trade.
Insider activity is descriptive. Nothing here is investment advice.
| 925 |
| $64.25 |
| $59k |
| 2026-10-15 | 9 co-filers President, Global Head of R&D | 10b5-1 plan sale | 2,642 | $112.71 | $298k |
| 2026-10-15 | 9 co-filers President, Global Head of R&D | Option exercise | 839 | $0.00 | — |
| 2026-10-15 | 9 co-filers President, Global Head of R&D | Option exercise | 423 | $0.00 | — |
| 2026-10-15 | 9 co-filers President, Global Head of R&D | Option exercise | 455 | $0.00 | — |
| 2026-10-15 | 9 co-filers President, Global Head of R&D | Option exercise | 925 | $0.00 | — |
| 2026-10-01 | Heeson Lee EVP, Head of Incyte Intl | Tax withholding | 463 | $117.14 | $54k |
| 2026-09-30 | Clancy Paul J Director | Grant | 203 | $121.35 | $25k |
| 2026-09-30 | Harrigan Edmund Director | Grant | 206 | $121.35 | $25k |
| 2026-09-30 | 12 co-filers Group filing | Grantindirect | 322 | $0.00 | $0 |
| 2026-09-30 | 12 co-filers Group filing | Grantindirect | 322 | $0.00 | $0 |
| 2026-09-22 | Gardner David H EVP, Chief Strategy Officer | Tax withholding | 920 | $126.93 | $117k |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | Option exercise | 2,957 | $61.76 | $183k |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | Option exercise | 4,551 | $61.18 | $278k |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | Option exercise | 6,477 | $64.25 | $416k |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | Option exercise | 9,233 | $71.93 | $664k |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | 10b5-1 plan sale | 9,233 | $120.50 | $1.1m |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | 10b5-1 plan sale | 13,985 | $120.49 | $1.7m |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | Option exercise | 2,957 | $0.00 | — |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | Option exercise | 4,551 | $0.00 | — |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | Option exercise | 6,477 | $0.00 | — |
| 2026-09-15 | 10 co-filers President, Global Head of R&D | Option exercise | 9,233 | $0.00 | — |
| 2026-08-25 | Basi Ramitpal K EVP, Human Resources | Tax withholding | 504 | $129.72 | $65k |
| 2026-08-19 | Cagnoni Pablo J President, Global Head of R&D | 10b5-1 plan sale | 10,801 | $125.56 | $1.4m |
| 2026-08-12 | Cagnoni Pablo J President, Global Head of R&D | 10b5-1 plan sale | 10,803 | $120.04 | $1.3m |
| 2026-08-05 | 3 co-filers EVP & Chief Scientific Officer | Option exercise | 2,207 | $106.47 | $235k |
| 2026-08-05 | Cagnoni Pablo J President, Global Head of R&D | 10b5-1 plan sale | 10,640 | $122.69 | $1.3m |
| 2026-08-05 | 3 co-filers EVP & Chief Scientific Officer | 10b5-1 plan sale | 2,207 | $123.99 | $274k |
| 2026-08-05 | 3 co-filers EVP & Chief Scientific Officer | Option exercise | 2,207 | $0.00 | — |
| 2026-08-03 | 44 co-filers EVP & Chief Scientific Officer | Option exercise | 6,055 | $105.43 | $638k |
| 2026-08-03 | 44 co-filers EVP & Chief Scientific Officer | 10b5-1 plan sale | 6,055 | $120.43 | $729k |
| 2026-08-03 | 44 co-filers EVP & Chief Scientific Officer | Option exercise | 6,055 | $0.00 | — |
| 2026-07-31 | Cagnoni Pablo J President, Global Head of R&D | 10b5-1 plan sale | 15,888 | $119.70 | $1.9m |
| 2026-07-31 | 44 co-filers EVP & Chief Scientific Officer | Option exercise | 2,918 | $61.18 | $179k |
| 2026-07-31 | 44 co-filers EVP & Chief Scientific Officer | Option exercise | 2,284 | $64.25 | $147k |
| 2026-07-31 | 44 co-filers EVP & Chief Scientific Officer | Option exercise | 2,709 | $61.76 | $167k |
| 2026-07-31 | 44 co-filers EVP & Chief Scientific Officer | Option exercise | 3,148 | $68.62 | $216k |